Back to News
Market Impact: 0.22
Iovance Biotherapeutics Consensus Price Target Increased by 34.74% to $13.06
Source: Nasdaq
Analyst EstimatesAnalyst InsightsHealthcare & Biotech
The aggregate one-year analyst price target for Iovance Biotherapeutics was raised 34.74% to $13.06 per share from $9.69 on September 11, 2026. The substantial upward revision signals improved analyst expectations for the biotech company, though the article provides no underlying earnings, clinical, or operational catalyst.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.38
Ticker Sentiment
IOVA0.48
More News
- Your health insurance premiums may take a big jump in 2027 — here's why
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Tesla reports 486,532 vehicle deliveries for third quarter, topping expectation
- Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
- Why AMD Stock Jumped 30% in September
- Nike falls to 13-year low. Why analysts don't think the selling is over yet